Skip to main content

Table 3 Result of the dosimetric evaluation between the clinical treatment plans, optimized based on the manually delineated structures and the same dose distribution overlayed on the uncorrected segmentations derived from the Pelvic U-Net

From: Pelvic U-Net: multi-label semantic segmentation of pelvic organs at risk for radiation therapy anal cancer patients using a deeply supervised shuffle attention convolutional neural network

p-values for evaluated pelvic OAR structures (\(\alpha = 0.05\))

 

DVH indicesa

Structure

Volume

V10Gy

V20Gy

V30Gy

V40Gy

V50Gy

Dosemean

TBM

 < 0.001

0.670

0.064

0.285

0.421

 < 0.001

0.583

Bladder

0.073

0.041

0.035

0.026

0.277

0.715

0.421

Bowel cavity

0.073

0.064

0.073

0.169

0.421

0.557

0.679

All bowel

0.007

0.010

0.026

0.055

0.095

0.175

0.561

Small bowel

0.229

0.268

0.241

0.390

0.583

0.765

0.160

Large bowel

0.073

0.107

0.107

0.229

0.208

0.160

0.151

  1. Bold values indicate statistically significant differences from a two-sided Wilcoxon signed rank test with a significance level of \({\upalpha } = 0.05\).
  2. OAR organs at risk, DVH dose-volume histogram, TBM total bone marrow
  3. aVolume [cm.3], V10Gy − V50Gy [%], Dosemean [Gy] for TBM
  4. Volume [cm3], V10Gy − V50Gy [cm.3], Dosemean [Gy] for bladder, bowel cavity, all bowel, small bowel, and large bowel